Skip to main content

Zelboraf FDA Approval History

FDA Approved: Yes (First approved August 17, 2011)
Brand name: Zelboraf
Generic name: vemurafenib
Dosage form: Tablets
Company: Genentech, Inc.
Treatment for: Melanoma, Metastatic

Zelboraf (vemurafenib) is a kinase inhibitor indicated for the treatment of patients with metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test, and for the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation.

Development timeline for Zelboraf

DateArticle
Nov  6, 2017Approval FDA Approves Zelboraf (vemurafenib) for Erdheim-Chester Disease with BRAF V600 Mutation
Aug 17, 2011Approval FDA Approves Zelboraf and Companion Diagnostic Test for Late-Stage Skin Cancer
May 11, 2011New Drug Applications Submitted in the United States and Europe for Vemurafenib in Advanced Skin Cancer

See also

Zelboraf (vemurafenib) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer